Delivery Order HHSN261201200033I-HHSN26100002
Award Date 9/20/13
Potential Completion Date 9/30/18
Potential Value $559K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Madison, WI 53715, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award, valued at $261,352.00, was issued by the National Cancer Institute (NCI) to the University of Wisconsin System (UW System) to conduct a randomized, double-blind, Phase I dose-escalation study of a novel retinoid called 9CUAB30. The contract is part of the NCI's Cancer Prevention Agent Development Program, which focuses on early-phase clinical research. As the prime contractor, the UW System will be responsible for performing the clinical study at its University of...
- This federal contract award was made by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Wisconsin - Madison, operating as Research and Sponsored Programs within the University of Wisconsin System. The $418,872.19 contract is for research and development related to the Cancer Prevention Agent Development Program, which is focused on early phase clinical research. This contract is a delivery order under the Cancer...
- This is a definitive contract awarded by the National Cancer Institute (NCI), a civilian agency of the Department of Health and Human Services (HHS), to the University of Wisconsin Hospitals and Clinics Authority (UWHCA) on September 15, 1999. The contract, valued at $2,765,970.00, is for a randomized controlled Phase II clinical trial to study the modulation of intermediate endpoint biomarkers, as described in Workstatement No. 61. The contract does not have a set-aside designation and is...
- The National Cancer Institute (NCI) awarded a $1,366,178.15 delivery order contract to the University of Wisconsin System to conduct a pilot study of daily exemestane in women with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or grade 1 endometrial cancer. This contract is part of the NCI's Cancer Prevention Agent Development Program, which focuses on early-phase clinical research. The contract does not have a set-aside designation and will run through...
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the U.S. government, to the University of Wisconsin System. The $1,214,305 contract is for a Phase I clinical trial to evaluate the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) that targets three breast cancer antigens (IGFBP-2, HER2, and IGF-IR). The contract is part of NCI's Cancer Prevention Agent Development Program, which focuses on early-stage clinical research. The...
- This is a Firm Fixed Price Delivery Order award under the National Cancer Institute's PREVENT Cancer Program Indefinite Delivery Contract (HHSN261201500037I). The prime contractor is The Medical College Of Wisconsin, Inc. (MCW), a private non-profit medical research institution. The award, valued at $598,803.88, is for examination of exosomal miRNAs as potential biomarkers for chemopreventive efficacy in mouse models of lung squamous cell carcinoma. This work will be performed by MCW from...
- This is a firm fixed-price delivery order contract issued by the Department of Health and Human Services' National Cancer Institute to the University of Alabama at Birmingham (UAB) for the "Prevention of Urinary Bladder Cancer with Two 'Clinically-Ready Agents (Everolimus and Naproxen) When Administered in Combination." The contract has a potential value of $432,272.00 and a completion date of April 30, 2020. It was awarded on July 9, 2018 and is part of the National Cancer Institute's...
- This federal contract award was issued by the National Cancer Institute (NCI), a part of the U.S. Department of Health and Human Services, to ICF Macro Inc., a subsidiary of ICF International, Inc. The $22,080,493 contract, which does not have a set-aside designation, is for a Campaigns and Monitoring period of performance from September 2016 to September 2017 to expand and promote NCI's tobacco cessation resources. The contract is a Blanket Purchase Agreement (BPA) Call and is priced on a...
- This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to the University of Alabama at Birmingham (UAB) for the further development of multi-antigen vaccines for the primary and secondary prevention of bladder cancer. The contract has a firm fixed price of $901,729.00 and a period of performance from September 17, 2018 to March 16, 2020, with a final completion date of December 16, 2022. The contract is part of...
- This is a $460,975.01 firm fixed-price delivery order awarded by the National Institutes of Health (NIH) National Cancer Institute to The Medical College of Wisconsin, Inc. (MCW), a private medical school and graduate institution. The contract is part of the NIH's "PREVENT Cancer Program (PREVENT)" and supports the "Preclinical Prevent Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers" major program. No set-aside designation was used. Through past...